Patent Settlements Blocking Authorized Generics May Get Supreme Court Review
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline and Teva hope that lower court disagreements, if not exactly a circuit split, will be enough to get high court to revisit its Actavis decision.